Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients. 2000

M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
Departments of Anaesthesiology and Intensive Care Therapy and General and Visceral Surgery, University of Jena, Bachstr. 18, D-07743 Jena, Germany.

The elimination of procalcitonin and the course of plasma concentrations during continuous veno-venous haemodiafiltration were measured in patients with sepsis or multiple organ dysfunction syndrome, because these patients are a main target group for the measurement of procalcitonin and often require renal replacement therapy. Procalcitonin was measured in the prefilter plasma and the filtrate at 5 min, 15 min and 1, 2, 4, 6, 12, 24 h after set-up of continuous veno-venous haemodiafiltration. In a prospective study, 19 patients with plasma levels of procalcitonin > 3 ng mL-1 and acute oliguric renal failure treated with continuous veno-venous haemodiafiltration using a polysulphone membrane, were evaluated for the study of clearance. Twenty-one control patients (procalcitonin < 2 ng mL-1) were studied to determine whether filtration itself induced a procalcitonin response. No interventions were required. In patients with low procalcitonin concentrations (procalcitonin < 2 ng mL-1) continuous veno-venous haemodiafiltration did not cause a rise in procalcitonin. In patients with increased procalcitonin plasma concentrations (> 3 ng mL-1), the protein was removed through the polysulphone membrane, with a final clearance of 4 mL min-1 after the initial adsorption period (clearance 0.4-0.9 mL min-1 during the first hour of continuous veno-venous haemodiafiltration). Thus, on the average, approximately 10% of plasma concentrations were measurable in the filtrate ultimately. However, procalcitonin plasma levels were not significantly altered during continuous veno-venous haemodiafiltration (86% of the initial concentration after 24 h). Although procalcitonin is removed from the plasma during continuous veno-venous haemodiafiltration in measurable amounts plasma procalcitonin concentrations did not change significantly during haemodiafiltration. Procalcitonin thus can also be used as a diagnostic parameter in patients undergoing continuous veno-venous haemodiafiltration.

UI MeSH Term Description Entries
D008297 Male Males
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009102 Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative. MODS,Multiple Organ Dysfunction Syndrome,Organ Dysfunction Syndrome, Multiple,Organ Failure, Multiple,Failure, Multiple Organ,Multiple Organ Failures
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011498 Protein Precursors Precursors, Protein
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
May 2000, The Journal of antimicrobial chemotherapy,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
April 2001, Intensive care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
December 2000, European journal of clinical pharmacology,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
August 2004, Journal of advanced nursing,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
January 1999, Critical care (London, England),
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
July 2004, The Journal of antimicrobial chemotherapy,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
April 2014, Clinical toxicology (Philadelphia, Pa.),
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
June 2002, Journal of pharmaceutical and biomedical analysis,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
October 1999, Intensive care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
September 1994, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!